Newsfeed

Serum Institute of India applies for emergency approval of covid vaccine candidate ‘Covishield’

Serum Institute of India (SII) has applied for emergency approval of made-in-India covid vaccine candidate, Covishield.

SII CEO Adar Poonawalla has confirmed it and said it will save countless lives.

He also thanked the Government of India and Prime Minister Narendra Modi for their invaluable support.

SII, the world’s largest vaccine producer by volume, had sought emergency use authorization in the country for AstraZeneca Plc’s COVID-19 vaccine candidate.

The company applied to the Drugs Controller General of India, citing unmet medical needs due to the pandemic and in the interest of the public at large. 

The move comes close on the heels of Pfizer Inc applying for a similar authorization of its coronavirus vaccine in India.

 

Support Ethical Journalism. Support The Dispatch

The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism


 

The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies